$7.93
+0.42 (+5.59%)
Open$8.01
Previous Close$7.51
Day High$8.01
Day Low$7.70
52W High$18.40
52W Low$7.08
Volume—
Avg Volume3.1K
Market Cap60.64M
P/E Ratio—
EPS$-1.76
SectorBiotechnology
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 13.14M | 13.93M | 11.00M |
| Net Income | -2,417,675 | -2,785,079 | -2,350,186 |
| Profit Margin | -18.4% | -20.0% | -21.4% |
| EBITDA | -3,490,436 | -4,206,535 | -3,083,781 |
| Free Cash Flow | -1,263,655 | -1,934,401 | -1,577,892 |
| Rev Growth | -4.0% | +11.1% | -5.6% |
| Debt/Equity | 0.43 | 0.38 | 0.34 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |